相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer et al.
LANCET (2020)
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
Jonathan S. Cebon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Glycolipid-peptide vaccination induces liver-resident memory CD8+ T cells that protect against rodent malaria
Lauren E. Holz et al.
SCIENCE IMMUNOLOGY (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
Michael Lattanzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Automated mapping of phenotype space with single-cell data
Nikolay Samusik et al.
NATURE METHODS (2016)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus
Ji-Li Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy
Robert Weinkove et al.
HAEMATOLOGICA (2013)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells
Andrew J. Nicol et al.
CLINICAL CANCER RESEARCH (2011)
Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+T Cells to Dendritic Cell-Based Vaccines
Troels R. Petersen et al.
PLOS ONE (2011)
Response definition criteria for ELISPOT assays revisited
Z. Moodie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
Troels R. Petersen et al.
IMMUNOLOGY AND CELL BIOLOGY (2010)
Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs
Verena Semmling et al.
NATURE IMMUNOLOGY (2010)
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection
Emanuela Martinuzzi et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma
Johan W. Molling et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
DH Chang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The peripheral blood Vα24+NKT cell numbers decrease in patients with haematopoietic malignancy
K Yoneda et al.
LEUKEMIA RESEARCH (2005)
Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity
M Nieda et al.
BLOOD (2004)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Modulation of human Vα24+Vβ11+ NKT cells by age, malignancy and conventional anticancer therapies
T Crough et al.
BRITISH JOURNAL OF CANCER (2004)
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
IF Hermans et al.
JOURNAL OF IMMUNOLOGY (2003)
Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
S Fujii et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo
D Stober et al.
JOURNAL OF IMMUNOLOGY (2003)
Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs
S Fujii et al.
NATURE IMMUNOLOGY (2002)
Impaired proliferative response of Vα24 NKT cells from cancer patients against α-galactosylceramide
K Yanagisawa et al.
JOURNAL OF IMMUNOLOGY (2002)
Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines
G Gonzalez-Aseguinolaza et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
分享论文
